We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Snap Inc. (SNAP - Free Report) , the parent of camera application Snapchat, has been in troubled waters for quite some time now. The latest slash in ad revenue forecast by market research firm, eMarketer bears testimony to the fact.
The research firm has projected Snap’s ad revenues in the United States for the current year to be $662.1 million, down from $1.03 billion projected in March. Moreover, the firm anticipates that the company will not be able to cross the $1 billion mark in U.S. ad revenues until 2020.
Though Snap’s shift to an automated or programmatic ad delivery system has increased the number of advertisers on the platform, it has resulted in lower ad prices, which is the primary reason behind the downgrade.
Although revenues on a year-over-year basis are expected to rise 18.7% in the current year, the figure is way below last year’s growth of 85.6%. A rebound in revenues in the next two years is however expected by the firm.
Moreover, the firm has also lowered projection for UK ad revenues. Snap is now expected to generate £68.4 million in UK ad revenues, compared with £104.8 million projected in March.
However, Snap’s UK ad revenues are expected to nearly double this year from £35.5 million generated last year.
In its report, eMarketer further added that Snapchat currently accounts for 0.5% of UK’s digital ad market, up 20 basis points from 2017. However, the platform is way behind Alphabet’s (GOOGL - Free Report) Google and Facebook , which control 39.1% and 21.7% of the digital ad market in the UK, respectively.
Coming to user growth, eMarketer predicts that Snapchat’s monthly active users (MAU) in the United States will increase 7% year over year to 84.8 million at the end of 2018. The growth is higher than that of Facebook and Twitter , which is anticipated to grow 0.9%, but is lower than Instagram’s 13.1%.
Moreover, per the firm, in the user group aged 12-17, Snapchat will add 1.2 million new users by 2022, while Facebook will lose 2.2 million users in that demography.
eMarketer also predicts that Snapchat’s MAUs in the UK will increase 8.6% year on year to 16.2 million, surpassing Facebook and Twitter’s 2% and 1.9% growth respectively. However, the platform will trail Instagram, which is anticipated to grow 9.7%.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Snapchat Woes Mount, eMarketer Cuts 2018 Revenue Forecast
Snap Inc. (SNAP - Free Report) , the parent of camera application Snapchat, has been in troubled waters for quite some time now. The latest slash in ad revenue forecast by market research firm, eMarketer bears testimony to the fact.
The research firm has projected Snap’s ad revenues in the United States for the current year to be $662.1 million, down from $1.03 billion projected in March. Moreover, the firm anticipates that the company will not be able to cross the $1 billion mark in U.S. ad revenues until 2020.
Though Snap’s shift to an automated or programmatic ad delivery system has increased the number of advertisers on the platform, it has resulted in lower ad prices, which is the primary reason behind the downgrade.
Although revenues on a year-over-year basis are expected to rise 18.7% in the current year, the figure is way below last year’s growth of 85.6%. A rebound in revenues in the next two years is however expected by the firm.
Moreover, the firm has also lowered projection for UK ad revenues. Snap is now expected to generate £68.4 million in UK ad revenues, compared with £104.8 million projected in March.
However, Snap’s UK ad revenues are expected to nearly double this year from £35.5 million generated last year.
In its report, eMarketer further added that Snapchat currently accounts for 0.5% of UK’s digital ad market, up 20 basis points from 2017. However, the platform is way behind Alphabet’s (GOOGL - Free Report) Google and Facebook , which control 39.1% and 21.7% of the digital ad market in the UK, respectively.
Snap Inc. Revenue (Quarterly YoY Growth)
Snap Inc. Revenue (Quarterly YoY Growth) | Snap Inc. Quote
Other Snippets from the Report
Coming to user growth, eMarketer predicts that Snapchat’s monthly active users (MAU) in the United States will increase 7% year over year to 84.8 million at the end of 2018. The growth is higher than that of Facebook and Twitter , which is anticipated to grow 0.9%, but is lower than Instagram’s 13.1%.
Moreover, per the firm, in the user group aged 12-17, Snapchat will add 1.2 million new users by 2022, while Facebook will lose 2.2 million users in that demography.
eMarketer also predicts that Snapchat’s MAUs in the UK will increase 8.6% year on year to 16.2 million, surpassing Facebook and Twitter’s 2% and 1.9% growth respectively. However, the platform will trail Instagram, which is anticipated to grow 9.7%.
Snap currently has a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>